What growth-hormone peptides actually are, and the one the FDA cleared

Walk through any peptide listing and you'll hit a cluster of names that seem to promise the same thing: sermorelin, CJC-1295, ipamorelin, tesamorelin, and a handful of others sold in blends. The marketing tends to file them under one heading, "growth hormone peptides," as if they were interchangeable. They aren't. Two of them work by pressing on different buttons, and only one of the whole set carries a full FDA approval. The category is worth mapping, because the label hides most of what actually distinguishes these compounds.

Two ways to nudge the same gland

None of these peptides is growth hormone. That's the first thing the name gets wrong. They are secretagogues, which means they coax the pituitary into making and releasing more of its own GH rather than adding hormone from outside. And they do it along two separate pathways.

The first group are GHRH analogs. They copy growth-hormone-releasing hormone, the signal the hypothalamus normally sends to tell the pituitary to produce GH. Sermorelin, tesamorelin, and CJC-1295 all sit here. The second group are ghrelin mimetics, sometimes called GHRPs. They act on a different receptor, the one ghrelin uses, and trigger a sharper pulse of release. Ipamorelin is the tidiest example, and it's often paired with a GHRH analog precisely because the two routes complement each other: one raises the baseline, the other adds the pulse.

That pairing logic is real pharmacology. It is also the reason the blends exist, and the reason it's easy to lose track of what any single ingredient is doing.

The one with an approval

Tesamorelin is the outlier. It's a stabilized, 44-amino-acid GHRH analog, sold as Egrifta, and the FDA approved it in 2010 for a single narrow use: reducing the excess visceral abdominal fat that some people develop with HIV-associated lipodystrophy. A more concentrated formulation cleared in 2025. In its pivotal trials, daily tesamorelin lowered visceral fat by roughly 15 to 18 percent over about six months, which is the kind of measured, published result the rest of the category doesn't have.

Read that approval precisely, because it is narrow on purpose. It says the agency looked at tesamorelin in one condition, in one population, and found the evidence sufficient there. It does not say anything about the longer list of uses the peptide gets discussed for, and it certainly doesn't extend to sermorelin or ipamorelin, which are chemically different compounds with their own, thinner files.

What "off-label" and "research chemical" actually mean

Here is where the category splits. Tesamorelin has a defined dose, large-trial safety data, and a label. Sermorelin, CJC-1295, and ipamorelin mostly circulate as compounded preparations or as products stamped "for research use only." That stamp is not a technicality. It means the compound has not been through the review that would let it be marketed for people to use, and that whatever human data exist are limited compared with what a full approval requires.

None of that makes the underlying biology fake. The receptors are real, the mechanisms are describable, and some of these peptides have been studied in serious settings. But "studied" and "approved for you to use" are different statements, and the gap between them is exactly what the shared label papers over.

How to hold the category

The useful move is to stop treating "growth hormone peptides" as one thing. Ask, for any single name, three plain questions. Which pathway does it use, GHRH or ghrelin? Is it approved, and if so, for whom and for what? And how much of what's claimed for it rests on human trials rather than on mechanism and animal work?

Run tesamorelin through that and you get a clear, bounded answer: GHRH analog, approved, for one specific condition, with real trial numbers behind it. Run most of the others through it and the honest reply is quieter. Interesting mechanism, no full approval, evidence still thin. That's not a verdict on any of them. It's just the map the marketing leaves out.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.